Skip to main content
. Author manuscript; available in PMC: 2013 Oct 17.
Published in final edited form as: Mol Cancer Res. 2013 Jan 30;11(4):370–380. doi: 10.1158/1541-7786.MCR-12-0491

Figure 3. Depletion of additional origin licensing components in U20S enhances HU sensitivity.

Figure 3

U2OS cells were transfected with 0.6 nM siRNA for 48 hours. (A) Immunoblotting using α-ORC6 and α-CDC6. (B) Viability was assessed as in Fig. 1D-E. (C) Estimated IC50 values.